Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the sixteen analysts that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and fourteen have issued a buy recommendation on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $48.64.
A number of equities analysts have commented on the stock. Argus boosted their price target on shares of Teva Pharmaceutical Industries from $42.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, November 17th. JPMorgan Chase & Co. raised their price objective on shares of Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. Barclays lifted their price objective on shares of Teva Pharmaceutical Industries from $47.00 to $50.00 and gave the stock an “overweight” rating in a report on Thursday. Piper Sandler upped their target price on shares of Teva Pharmaceutical Industries from $44.00 to $56.00 and gave the stock an “overweight” rating in a research report on Thursday, November 12th. Finally, TD Cowen upped their target price on shares of Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th.
View Our Latest Analysis on Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Stock Performance
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, topping the consensus estimate of $0.72 by $0.14. The company had revenue of $4.39 billion during the quarter, compared to analyst estimates of $4.23 billion. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. Teva Pharmaceutical Industries’s revenue was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.78 earnings per share. As a group, equities analysts forecast that Teva Pharmaceutical Industries will post 1.98 earnings per share for the current fiscal year.
Insider Activity
In other news, insider Mark Sabag sold 46,000 shares of the stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $41.93, for a total transaction of $1,928,780.00. Following the transaction, the insider directly owned 80,760 shares in the company, valued at approximately $3,386,266.80. This represents a 36.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Richard D. Francis sold 250,000 shares of the firm’s stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $42.24, for a total value of $10,560,000.00. Following the transaction, the chief executive officer directly owned 927,529 shares in the company, valued at approximately $39,178,824.96. This represents a 21.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 715,945 shares of company stock valued at $29,061,351. 0.54% of the stock is owned by insiders.
Institutional Trading of Teva Pharmaceutical Industries
Several hedge funds and other institutional investors have recently bought and sold shares of TEVA. Root Financial Partners LLC purchased a new position in shares of Teva Pharmaceutical Industries during the third quarter worth approximately $33,000. Western Wealth Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter valued at $43,000. Sunbelt Securities Inc. purchased a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter valued at $45,000. CX Institutional purchased a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at $54,000. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Teva Pharmaceutical Industries by 64.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,658 shares of the company’s stock valued at $50,000 after purchasing an additional 647 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.
More Teva Pharmaceutical Industries News
These are some of the TEVA news items that stood out recently:
- Positive Sentiment: Zacks Research moved its rating from “strong sell” to “hold.” Barclays also raised its price target to $50 from $47 and maintained an “overweight” rating, signaling analysts see potential upside. Read rating information
- Neutral Sentiment: CEO Richard Francis and other executives are scheduled to present at three healthcare investor conferences. The appearances could provide updates, but no new business developments were announced. Read announcement
- Negative Sentiment: Investors remain focused on the departure of Global R&D chief and Chief Medical Officer Eric Hughes, which previously prompted a sharp stock decline. Teva says its strategy, R&D priorities and expectations are unchanged, and it is searching for a successor, but leadership uncertainty may weigh on sentiment. Read announcement
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.
See Also
- Five stocks we like better than Teva Pharmaceutical Industries
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.
